0001104659-20-096098.txt : 20200817
0001104659-20-096098.hdr.sgml : 20200817
20200817160645
ACCESSION NUMBER: 0001104659-20-096098
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200813
FILED AS OF DATE: 20200817
DATE AS OF CHANGE: 20200817
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Andrade Robert
CENTRAL INDEX KEY: 0001468308
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32295
FILM NUMBER: 201110152
MAIL ADDRESS:
STREET 1: C/O ADHEREX TECHNOLOGIES INC.
STREET 2: 4620 CREEKSTONE DRIVE, SUITE 200
CITY: DURHAM
STATE: NC
ZIP: 27703
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: FENNEC PHARMACEUTICALS INC.
CENTRAL INDEX KEY: 0001211583
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: PO BOX 13628
STREET 2: 68 TW ALEXANDER DRIVE
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
BUSINESS PHONE: (919) 636-4530
MAIL ADDRESS:
STREET 1: PO BOX 13628
STREET 2: 68 TW ALEXANDER DRIVE
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
FORMER COMPANY:
FORMER CONFORMED NAME: FENNEC PHARMACEUTICALS, INC.
DATE OF NAME CHANGE: 20140903
FORMER COMPANY:
FORMER CONFORMED NAME: ADHEREX TECHNOLOGIES INC
DATE OF NAME CHANGE: 20021223
4
1
tm2028839d2_4.xml
OWNERSHIP DOCUMENT
X0306
4
2020-08-13
0
0001211583
FENNEC PHARMACEUTICALS INC.
FENC
0001468308
Andrade Robert
68 TW ALEXANDER DRIVE, PO BOX 13628
DURHAM
NC
27709
0
1
0
0
Chief Financial Officer
Common shares
2020-08-13
4
M
0
323961
1.85
A
341011
D
Common shares
2020-08-13
4
F
0
97136
6.17
D
243875
D
Common shares
2020-08-13
4
F
0
38828
5.77
D
205047
D
Common shares
2020-08-14
4
F
0
38900
5.68
D
166147
D
Common shares
2020-08-17
4
F
0
12874
5.71
D
153273
D
Represents options granted on August 18, 2010 with a CAD$ strike price of $2.43 CAD converted at 0.76 CAD/USD exchange ratio with an expiration of August 18, 2020.
Represents shares sold per a net exercise of shares to cover the proceeds necessary for the exercise of 323,861 shares at a USD$1.85 exercise price from the August 18, 2010 grant of 323,961 shares with expiration of August 18, 2020.
Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the exercise of 323,861 shares from an August 18, 2010 grant of 323,961 shares. The price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $5.62 to $5.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the exercise of 323,861 shares from an August 18, 2010 grant of 323,961 shares. The price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $5.39 to $5.77 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the exercise of 323,861 shares from an August 18, 2010 grant of 323,961 shares. The price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $5.63 to $5.80 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
/s/ Robert Andrade, Robert Andrade, Chief Financial Officer
2020-08-17